FREDERICK, Md., Jan. 19, 2012 /PRNewswire/ -- BioElectronics Corporation. (OTC-PINK: BIEL), the maker of inexpensive, disposable drug-free topical pain and healing devices, today announced the acceptance for publication of an article in the peer reviewed journal The Journal of Foot and Ankle Surgery. The article documents the clinical trial results of BioElectronics' study of its medical device on plantar fasciitis.
Plantar fasciitis, or heel pain, is a very common complaint which affects up to two million people in the United States yearly, in a multi-million dollar treatment market. Plantar fasciitis heel pain, with the current treatment options, can persist up to one or two years and can be extremely painful and debilitating.
"With this published clinical trial, which was a placebo controlled, randomized and double blind study, BioElectronics is demonstrating that its patented pulsed radiofrequency electromagnetic field therapy medical device offers a rapid and economical resolution of the heel pain, and consequently is a significant advancement over current treatment options," said Ian Rawe, PhD, BioElectronics Director of Clinical Research. "The publication of these results will help introduce to the medical community a drug-free treatment featuring our unique medical device as an orthopedic pain therapy. We anticipate strong interest which will lead to expanded clinical study on a variety of orthopedic conditions."
BioElectronics is currently conducting a second clinical study on plantar fasciitis using its revolutionary 'Smart Insole,' which provides a simple, 24-hour treatment option. With this new study, BioElectronics anticipates that it is moving toward making its therapy the treatment of choice in people suffering from plantar fasciitis.
About BioElectronics Corporation
BioElectronics is an award winning medical device developer and manufacturer of advanced medical devices. Its
|SOURCE BioElectronics Corporation|
Copyright©2010 PR Newswire.
All rights reserved